PredxBio and Hamamatsu Photonics Join Forces for Innovative Cancer Research Solutions

PredxBio and Hamamatsu Photonics Join Forces for Innovative Cancer Research Solutions



In an exciting development for cancer research, PredxBio, known for its advancements in AI-driven spatial biomarker discovery, has announced a strategic partnership with Hamamatsu Photonics K.K., a global leader in imaging technology. This collaboration aims to advance spatial biology solutions specifically tailored for cancer research and therapeutic advancement.

Merging Expertise for Breakthroughs


The partnership leverages Hamamatsu's state-of-the-art MoxiePlex™ multiplex immunofluorescence imaging system, which has the ability to capture up to ten fluorescent markers simultaneously. This capability is crucial for the precise spatial mapping of proteins found on cancer and immune cells within the tumor microenvironment. Launched in late 2024, MoxiePlex™ is designed for research use, allowing researchers to address the complex demands of spatial proteomics while maintaining simplicity in workflow, with the potential for clinical applications in immunotherapy response profiling in the future.

James Butler, Vice President of Marketing at Hamamatsu Corporation, emphasizes the vision that underpins this partnership: “This collaboration embodies our commitment to unlocking the true potential of spatial proteomics through innovation and accessibility.” Combining MoxiePlex™ with PredxBio’s SpaceIQ™ spatial analytics platform promises to create an integrated workflow that supports both basic and translational research in immuno-oncology.

An Integrated Ecosystem


The synergy of these technologies results in a streamlined, plug-and-play ecosystem for researchers. This setup enables a seamless transition from image capture to actionable insights, effectively facilitating tasks such as spatial immune cell profiling, pathway activation analysis, and biomarker stratification with unprecedented speed and clarity.

Dr. Dusty Majumdar, CEO of PredxBio, expressed enthusiasm about the collaboration, stating, “We’re excited to partner with Hamamatsu to bridge the gap between image generation and spatial intelligence. Our joint solution not only identifies protein expressions but also elucidates their spatial context and functional impact on disease biology. This empowers researchers and drug developers with valuable insights.”

A Commitment to Innovation


Both PredxBio and Hamamatsu are dedicated to simplifying spatial workflows while enhancing the biological resolution of their research outputs. The integration of these technologies fosters spatially resolved proteomic data to aid translational research, biomarker validation, and optimization of clinical trials.

About PredxBio


PredxBio is recognized as a leading spatial analytics entity headquartered in Pittsburgh, PA. The company specializes in harnessing AI to power next-generation cancer therapeutics through spatial biomarker innovations. PredxBio’s proprietary methods involve delving deep into drug mechanisms of action and predicting patient outcomes with over 90% accuracy. Through transforming multiplexed biopsy imagery and multi-modal spatial data into actionable insights, PredxBio aims to redefine standards in biomarker discovery and clinical research.

About Hamamatsu Photonics


Hamamatsu Photonics stands at the forefront of photonics technology, providing advanced imaging and optical systems. Their MoxiePlex™ platform is a cutting-edge multiplex immunofluorescence imaging solution for research, designed to enhance spatial proteomics research, particularly in the realms of immuno-oncology and broader pathological applications. The collaboration with PredxBio is poised to accelerate advancements in cancer research, showcasing their commitment to innovation and improved outcomes in the field.

This strategic alliance sets the stage for significant breakthroughs in cancer research, providing the necessary tools for researchers to explore complex biological mechanisms and paving the way for future clinical applications.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.